|
Market Report
|

Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
With sales growth rates expected to fall below their historic levels, Big Pharma must act to bolster its performance out to 2012 if it is to maintain the investment community's valuation of its stocks. One mechanism for plugging the sales growth rate gap and fulfilling investors' 'growth imperative' is M&A activity.
|
|
Read more...
|
|
|
Market Report
|
|
An Analysis of Access to Finance for European Biotechnology Firms
The financial contest is probably the biggest barrier to European competitiveness in biotechnology. Very young start-up companies frequently struggle to raise cash to start the business. It is becoming more difficult than before. However, there are an increasing number of national and regional schemes that provide money to young companies.
Full 43 pages report is available for free at our Downloads section.
|
|
Read more...
|
|
|
Market Report
|

'Conservative' pharmaceutical industry slow to take advantage of online marketing opportunities
While the internet has altered the landscape in the retail sector and revolutionized the airline industry, pharmaceutical companies have been slow to take advantage of the marketing opportunities offered by the medium. With existing sales and marketing strategies widely considered unsustainable, the industry needs to evolve and engage with its customers online, or it risks being left behind.
|
|
Read more...
|
|
|
Market Report
|

Drug Repositioning Strategies - Serendipity by design
Drug repositioning has several advantages over traditional discovery-reduced cost, risk and time to market-compared with traditional discovery, providing an attractive prospect for Big Pharma, scrambling to fill pipelines in an increasingly harsh market environment. As competition to inlicense candidates drives the price of this strategy up, repositioning presents a cost effective alternative.
|
|
Read more...
|
|
|
Market Report
|
Osteoarthritis - The COX-2 pipeline collapses
With several recent non-approvable decisions in the osteoarthritis market since 2006, Datamonitor has updated its forecast to account for the effect on the market. We have revised the market outlook over the next 10 years using the latest IMS data. We expect the market to grow steadily, with a CAGR from 2007 to 2017 of 3.2%, to reach sales of nearly $5.5 billion in 2017.
|
|
Read more...
|
|
|
Market Report
|

Acute Stroke: Commercial risk offsets high unmet need
Stroke is one of the top three causes of death and its incidence in the seven major markets is expected to increase in the next ten years because of an aging population. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor.
|
|
Read more...
|
|
|
Market Report
|

Online Patient Recruitment Strategies - Optimizing the clinical trial process
With the rising costs, length and complexity of clinical trials, drug development is subject to huge delays, translating into delays in getting a drug to market and millions of dollars in lost sales. Optimizing the recruitment process through web-based technologies can cut delays in clinical trials and can also be used to maintain relationships with patients to improve the clinical trial process.
|
|
Read more...
|
|
|
Market Report
|

Pricing & Reimbursement - Seven Major Markets Update
Governments and payers across the seven major markets are implementing cost-cutting initiatives to combat escalating healthcare costs, putting even greater pressure on pharma companies. In addition to the credit crunch, ever fewer novel products are coming to market, contributing to the declining return on investment.
|
|
Read more...
|
|
|
Market Report
|

The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends
Emerging Role of Postmarketing Clinical Research is a report published by Business Insights that uses detailed case studies and market scenarios to examine the latest issues surrounding phase IV trial applications. The potential to leverage competitive advantage with postmarketing research is assessed by measuring the implications for formulary access, product marketing, indication expansion and reimbursement coverage.
|
|
Read more...
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
| Results 28 - 36 of 238 |